Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  Huang, Jing ^a,b,c,d   Liu, Gang ^a,b,c,d   Zhang, Yi miao ^a,b,c,d   Cui, Zhao ^a,b,c,d   Wang, Fang ^a,b,c,d   Liu, Xiao jing ^a,b,c,d   Chu, Rong ^a,b,c,d   Zhao, Ming hui ^a,b,c,d,e  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^e Tsinghua University   (China)

Author keywords

Focal segmental glomerulosclerosis; Podocyte; Urinary soluble urokinase receptor

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA3 INTEGRIN; BLOCKING ANTIBODY; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PREDNISONE; UROKINASE RECEPTOR;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GLOMERULAR FILTRATION BARRIER; HEMATURIA; HUMAN; KIDNEY BIOPSY; KIDNEY CONCENTRATING CAPACITY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PATHOGENESIS; PODOCYTE; PROTEIN URINE LEVEL; PROTEINURIA; REMISSION; URINALYSIS; URINARY EXCRETION; BLOOD; CASE CONTROL STUDY; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; METABOLISM; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; URINE; CELL DIFFERENTIATION; ELISA KIT; HUMAN CELL;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; INTEGRIN BETA3; MALE; MIDDLE AGED; PODOCYTES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SEVERITY OF ILLNESS INDEX;

EID: 84904731774     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-12-81     Document Type: Article

References (37)

1. Rich AR. A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis. Bull Johns Hopkins Hosp 1957, 100:173-186.
2. D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med 2011, 365:2398-2411. 10.1056/NEJMra1106556, 22187987.
3. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004, 43:368-382. 10.1053/j.ajkd.2003.10.024, 14750104.
4. D'Agati VD. Podocyte injury in focal segmental glomerulosclerosis: lessons from animal models (a play in five acts). Kidney Int 2008, 73:399-406. 10.1038/sj.ki.5002655, 17989648.
5. Kriz W. The pathogenesis of 'classic' focal segmental glomerulosclerosis-lessons from rat models. Nephrol Dial Transplant 2003, 18:vi39-vi44.
6. Asanuma K, Mundel P. The role of podocytes in glomerular pathobiology. Clin Exp Nephrol 2003, 7:255-259. 10.1007/s10157-003-0259-6, 14712353.
7. Hickson LJ, Gera M, Amer H, Iqbal CW, Moore TB, Milliner DS, Cosio FG, Larson TS, Stegall MD, Ishitani MB, Gloor JM, Griffin MD. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009, 87:1232-1239. 10.1097/TP.0b013e31819f12be, 19384172.
8. Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994, 23:574-581. 10.1016/S0272-6386(12)80381-7, 8154495.
9. Haas M, Godfrin Y, Oberbauer R, Yilmaz N, Borchhardt K, Regele H, Druml W, Derfler K, Mayer G. Plasma immunadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 1998, 13:2013-2016. 10.1093/ndt/13.8.2013, 9719156.
10. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996, 334:878-883. 10.1056/NEJM199604043341402, 8596570.
11. McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010, 5:2115-2121. 10.2215/CJN.03800609, 20966123.
12. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011, 17:952-960. 10.1038/nm.2411, 21804539.
13. Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Chen Y, Zhao MH. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 2013, 84:366-372. 10.1038/ki.2013.55, 23447064.
14. Maas RJ, Wetzels JF, Deegens JK. Serum-soluble urokinase receptor concentration in primary FSGS. Kidney Int 2012, 81:1043-1044.
15. Bock ME, Price HE, Gallon L, Langman CB. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol 2013, 8:1304-1311. 10.2215/CJN.07680712, 23620441.
16. Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 2013, 96:394-399. 10.1097/TP.0b013e3182977ab1, 23736353.
17. Schwartz MM. Focal segmental glomerulosclerosis. Hepinstall's Pathology of the Kidney, Volume 2 2007, 156-204. Philadelphia: Lippincott Williams & Wilkins, Jennette JC, Olson JL, Schwartz MM, Silva FG, 6.
18. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 2002, 13:630-638.
19. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J, PodoNet and FSGS CT Study Consortia Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012, 23:2051-2059. 10.1681/ASN.2012030302, 3507361, 23138488, PodoNet and FSGS CT Study Consortia.
20. Kemper MJ, Wei C, Reiser J. Transmission of glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child. Am J Kidney Dis 2013, 61:352. 10.1053/j.ajkd.2012.10.011, 23182533.
21. Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008, 14:55-63. 10.1038/nm1696, 18084301.
22. Zhang B, Xie S, Shi W, Yang Y. Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant 2012, 27:1746-1755. 10.1093/ndt/gfr612, 22076430.
23. Stokes MB, Valeri AM, Markowitz GS, D'Agati VD. Cellular focal segmental glomerulosclerosis: clinical and pathologic features. Kidney Int 2006, 70:1783-1792. 10.1038/sj.ki.5001903, 17021605.
24. Thomas DB, Franceschini N, Hogan SL, Ten Holder S, Jennette CE, Falk RJ, Jennette JC. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006, 69:920-926. 10.1038/sj.ki.5000160, 16518352.
25. D'Agati VD, Alster JM, Jennette JC, Thomas DB, Pullman J, Savino DA, Cohen AH, Gipson DS, Gassman JJ, Radeva MK, Moxey-Mims MM, Friedman AL, Kaskel FJ, Trachtman H, Alpers CE, Fogo AB, Greene TH, Nast CC. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol 2013, 8:399-406. 10.2215/CJN.06100612, 3586971, 23220425.
26. Enocsson H, Wetterö J, Skogh T, Sjöwall C. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. Transl Res 2013, 162:287-296. 10.1016/j.trsl.2013.07.003, 23916811.
27. Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011, 15:R63. 10.1186/cc10037, 3221996, 21324198.
28. Slot O, Brünner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 1999, 58:488-492. 10.1136/ard.58.8.488, 1752924, 10419867.
29. Yilmaz G, Köksal I, Karahan SC, Mentese A. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic inflammatory response syndrome. Clin Biochem 2011, 44:1227-1230. 10.1016/j.clinbiochem.2011.07.006, 21816136.
30. Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009, 27:157-172. 10.1155/2009/504294, 3835059, 19893210.
31. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 1999, 82:298-304.
32. Mazar AP, Henkin J, Goldfarb RH. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 1999, 3:15-32. 10.1023/A:1009095825561, 14517441.
33. Høyer-Hansen G, Rønne E, Solberg H, Behrendt N, Ploug M, Lund LR, Ellis V, Danø K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992, 267:18224-18229.
34. Pliyev BK. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87). Mol Cell Biochem 2009, 321:111-122. 10.1007/s11010-008-9925-z, 18830568.
35. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010, 11:23-36. 10.1038/nrm2821, 20027185.
36. Madsen CD, Sidenius N. The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur J Cell Biol 2008, 87:617-629. 10.1016/j.ejcb.2008.02.003, 18353489.
37. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol 2007, 177:927-939. 10.1083/jcb.200612058, 2064291, 17548516.